transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2014-0-2-97-104transmed-18Research ArticleКАРДИОЛОГИЯCARDIOLOGYПрофилактика инсульта при неклапанной форме фибрилляции предсердийSTROKE PREVENTION IN NON-VALVULAR FORM OF ATRIAL FIBRILLATIONНовиковаТатьяна НиколаевнаNovikovaTatiana N.noemail@neicon.ruСеверо-Западный государственный медицинский университет им. И.И. МечниковаРоссияNorth-Western State Medical University n.a. I.I. MechnikovRussian Federation20142312201602512Copyright © Новикова Т.Н., 20162016Новикова Т.Н.Novikova T.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/18

В статье представлен анализ современных подходов к стратификации риска развития ишемического инсульта и системных тромбоэмболий у больных неклапанной формой фибрилляции предсердий, а также риска развития больших кровотечений на фоне антитромботической терапии. Дана сравнительная характеристика новых пероральных антикоагулянтов.

The article presents the analysis of modern approaches to risk stratification of development of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation and also risk stratification of major bleeding on a background of antithrombotic therapy. The comparative characteristic of new oral anticoagulants is given.

фибрилляция предсердийинсультновые пероральные антикоагулянтыatrial fibrillationstrokenew oral anticoagulantsReferencesAnderson K.K., Olsen T.S., Dehlendorff C. et al. Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors // Stroke. - 2009. - Vol. 40. - P. 2068-2072.Anderson K.K., Olsen T.S., Dehlendorff C. et al. Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors // Stroke. - 2009. - Vol. 40. - P. 2068-2072.Savelieva I., Bajpai A., Camm A.J. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices // Ann. Med. - 2007. - Vol. 39. - P. 71-91.Savelieva I., Bajpai A., Camm A.J. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices // Ann. Med. - 2007. - Vol. 39. - P. 71-91.Emmerich J., Heuzey J.-Y.L., Bath P.M.W., Connolly S.J. Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. // Eur. Heart. J. - 2005. - Vol. 7, Supp. C. - P. C28-C33.Emmerich J., Heuzey J.-Y.L., Bath P.M.W., Connolly S.J. Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. // Eur. Heart. J. - 2005. - Vol. 7, Supp. C. - P. C28-C33.Hannon N., Sheehan O., Kelly L. et al. Stroke associated with atrial fibrillation incidence and early outcomes in the north Dublin population stroke study // Cerebrovasc. Dis. - 2010. - Vol. 29. - P. 43-49.Hannon N., Sheehan O., Kelly L. et al. Stroke associated with atrial fibrillation incidence and early outcomes in the north Dublin population stroke study // Cerebrovasc. Dis. - 2010. - Vol. 29. - P. 43-49.Gladstone D.J., Bui E., Fang J. et al. Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated // Stroke. - 2009. - Vol. 40. - P. 235-240.Gladstone D.J., Bui E., Fang J. et al. Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated // Stroke. - 2009. - Vol. 40. - P. 235-240.Hart R.G., Pearce L.A., Rothbart R.M. et al. Stroke With Intermittent Atrial Fibrillation: Incidence and Predictors During Aspirin Therapy // J. Am. Coll. Cardiol. - 2000. - Vol. 35. - P. 183-187.Hart R.G., Pearce L.A., Rothbart R.M. et al. Stroke With Intermittent Atrial Fibrillation: Incidence and Predictors During Aspirin Therapy // J. Am. Coll. Cardiol. - 2000. - Vol. 35. - P. 183-187.Flaker G.C., Belew K., Beckman K. and the AFFIRM Investigators. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study // Am. Heart J. - 2005. - Vol. 149. - P. 657-663.Flaker G.C., Belew K., Beckman K. and the AFFIRM Investigators. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study // Am. Heart J. - 2005. - Vol. 149. - P. 657-663.Сулимов В.А., Голицин С.П., Панченко Е.П. и соавт. Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК и ВНОА, 2011 // Рациональная фармакотерапия в кардиологии. - 2011. - Т. 7, № 4, приложение. - С. 3-79.Сулимов В.А., Голицин С.П., Панченко Е.П. и соавт. Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК и ВНОА, 2011 // Рациональная фармакотерапия в кардиологии. - 2011. - Т. 7, № 4, приложение. - С. 3-79.Сулимов В.А., Голицин С.П., Панченко Е.П. и соавт. Диагностика и лечение фибрилляции предсердий // Рекомендации РКО, ВНОА и АССХ. - М., 2012. - 100 с.Сулимов В.А., Голицин С.П., Панченко Е.П. и соавт. Диагностика и лечение фибрилляции предсердий // Рекомендации РКО, ВНОА и АССХ. - М., 2012. - 100 с.Camm A.J., Kirchhof P., Lip G.Y. et al. Guidelines for the management of atrial fibrillation // Europ. Heart J. - 2010. - Vol. 31. - P. 2369-2429.Camm A.J., Kirchhof P., Lip G.Y. et al. Guidelines for the management of atrial fibrillation // Europ. Heart J. - 2010. - Vol. 31. - P. 2369-2429.Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation // Europ. Heart J. - 2012. - [Электронный ресурс] doi:10.1093/eurheartj/ehs253Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation // Europ. Heart J. - 2012. - [Электронный ресурс] doi:10.1093/eurheartj/ehs253Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the Euro Heart Survey on atrial fibrillation // Chest. - 2010. - Vol. 137. - P. 263-272.Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the Euro Heart Survey on atrial fibrillation // Chest. - 2010. - Vol. 137. - P. 263-272.Connolly S.J., Eikelboom J., Joyner C. et al. Apixa-ban in Patients with Atrial Fibrillation // N. Engl. J. Med. - 2011. - Vol. 364. - P. 806-817.Connolly S.J., Eikelboom J., Joyner C. et al. Apixa-ban in Patients with Atrial Fibrillation // N. Engl. J. Med. - 2011. - Vol. 364. - P. 806-817.Connolly S.J., Eikelboom J., Hirsh J. et al. ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable // Ann. Intern. Med. - 2011. - Vol. 155. - P. 579-586.Connolly S.J., Eikelboom J., Hirsh J. et al. ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable // Ann. Intern. Med. - 2011. - Vol. 155. - P. 579-586.Link K.P. The discovery of dicumarol and its sequels // Circulation. - 1959. - Vol. 19. - P. 97-107.Link K.P. The discovery of dicumarol and its sequels // Circulation. - 1959. - Vol. 19. - P. 97-107.Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation // Ann. Intern. Med. - 2007. - Vol. 146. - P. 857-867.Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation // Ann. Intern. Med. - 2007. - Vol. 146. - P. 857-867.Connolly S.J., Pogue J., Hart A. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controllled trial // Lancet. - 2006. - Vol. 367. - P. 1903-1912.Connolly S.J., Pogue J., Hart A. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controllled trial // Lancet. - 2006. - Vol. 367. - P. 1903-1912.Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation // N. Engl. J. Med. - 2009. - Vol. 361. - P. 1139-1151.Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation // N. Engl. J. Med. - 2009. - Vol. 361. - P. 1139-1151.ROCKET AF Study Investigators. Rivaroxaban - once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study // Am. Heart J. - 2010. - Vol. 159. - P. 340-347.ROCKET AF Study Investigators. Rivaroxaban - once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study // Am. Heart J. - 2010. - Vol. 159. - P. 340-347.Patel M.R., Mahaffey K.W., Garg J. et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in non-valvular atrial fibrillation // N. Engl. J. Med. - 2011. - Vol. 365. - P. 883-891.Patel M.R., Mahaffey K.W., Garg J. et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in non-valvular atrial fibrillation // N. Engl. J. Med. - 2011. - Vol. 365. - P. 883-891.Granger C.B., Alexander J.H., McMurray J.J. et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. - 2011. - Vol. 365, № 11. - P. 981.Granger C.B., Alexander J.H., McMurray J.J. et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. - 2011. - Vol. 365, № 11. - P. 981.Heidbuchel H., Verhamme P., Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation // Europace. - 2013. - Vol. 15. - P. 625-651. - [Электронный ресурс] doi:10.1093/europace/eut083Heidbuchel H., Verhamme P., Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation // Europace. - 2013. - Vol. 15. - P. 625-651. - [Электронный ресурс] doi:10.1093/europace/eut083

The authors declare that there are no conflicts of interest present.